Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Department of Defense is issuing a modification to the Bupropion HCL ER National Contract, invoking option year 3. This solicitation includes several modifications related to compliance and contract terms. Bidders should be aware of the specific requirements outlined in the modifications.
Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract.
Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation.
Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract.
Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation.
BUPROPION HCL ER NATIONAL CONTRACTS SOLICITATION
BUPROPION HCL ER is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.